but at this time, we don't have a predictive factor to choose between the monotherapy and the combination. it is clear that the combination works better with the separation of the curves from the beginning and an incre...
最常见的侵袭性亚型包括,外周T细胞淋巴瘤非特指型(PTCL-NOS)、血管免疫母细胞性T细胞淋巴瘤(AITL)、结外NK/T细胞淋巴瘤(ENKTL)鼻型、成人T细胞白血病/淋巴瘤(ATLL)、间变性淋巴瘤激酶(ALK)阳性间变大细胞淋巴瘤(ALCL)、ALK阴性间变大细胞淋巴瘤等,5年OS率仅有30%左右。 目前PTCL的一线方案常为以蒽环类或吉西...
Dr. Andre:The trial is positive, with an incredible hazard ratio of 0.21 and a huge difference between the two arms - 72% of patients are progression-free in the NIVO + IPI compared to 14% in the chemotherapy arm ...
At 6 months, the overall survival (OS) was 56.5% (95% CI, 36.5%-76.5%), and the median OS was 7.1 months (95% CI, 5.1-9.1). “Patients who did not have rapid progression on prior systemic therapy appeared to have a more favorable survival in comparison with r...
Patients could not have received prior chemotherapy and must have had at least 2 prior lines of endocrine therapy with or without targeted therapy for metastatic disease; or received 1 line of therapy for metastatic disease and developed progression wi...
The estimated PFS rates in each respective arm were 25.9% vs 19.8% at 9 months, 21.2% vs 15.9% at 12 months, and 14.8% vs 5.9% at 18 months. Exploratory and post hoc analyses based on baseline characteristics highlighted a median PFS of 5.6 months with nivolumab plus chemotherapy vs 5.4...
1 Patients received atezolizumab at a dose of 15 mg/kg IV every 3 weeks in addition to 1 of 3 chemotherapy doublets: carboplatin paired with paclitaxel, pemetrexed (nonsquamous histology only), or nab-paclitaxel. Treatment continued for 4 to 6 cycles, followed by atezolizumab maintenance therapy...
(Median OS: not reached vs 13.8 months, P< 0.001; Median PFS: 13.0 months vs 2.7 months, P< 0.001). The best overall objective response rate (ORR) was also better with TACE-Len-T treatment (ORR: 72.1% vs 29.4%, P< 0.001), and the disease control rate (DCR) significantly increased...
at the trials that have been done in platinum resistant, the AURELIA trial was a great trial. It was very, in my mind, you know real-world, [in which] patients were either going to get treated with chemotherapy or chemotherapy and Avastin that recurred within 6 months. And and it was...
The median duration of exposure was 2.1 months (range: 1 day to 25 months). Adverse reactions that occurred at a ≥10% higher rate in pediatric patients when compared to adults were pyrexia (33%), leukopenia (31%...